tbuckley/cabot-search huggingface dataset:
Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Authors: E. Felip Font, S.N. Gettinger, M.A. Burgio, S.J. Antonia, E. Holgado, D.R. Spigel, O. Arrieta, M. Domine Gomez, O. Aren Frontera, J. Brahmer, L.Q. Chow, L. Crinò, C. Butts, B. Coudert, L. Horn, M. Steins, W.J. Geese, A. Li, D. Healey, E.E. Vokes
Journal: Annals of Oncology (2017)
Defining total-body AIDS-virus burden with implications for curative strategies
Authors: Jacob D Estes, Cissy Kityo, Francis Ssali, Louise Swainson, Krystelle Nganou Makamdop, Gregory Q Del Prete, Steven G Deeks, Paul A Luciw, Jeffrey G Chipman, Gregory J Beilman, Torfi Hoskuldsson, Alexander Khoruts, Jodi Anderson, Claire Deleage, Jacob Jasurda, Thomas E Schmidt, Michael Hafertepe, Samuel P Callisto, Hope Pearson, Thomas Reimann, Jared Schuster, Jordan Schoephoerster, Peter Southern, Katherine Perkey, Liang Shang, Stephen W Wietgrefe, Courtney V Fletcher, Jeffrey D Lifson, Daniel C Douek, Joseph M McCune, Ashley T Haase, Timothy W Schacker
Journal: Nature Medicine (2017)
Reducing health inequalities and monitoring social determinants of health in the European Union: a priority of the Spanish Presidency of the European Union 2010
Authors: Collective Technical Committee for the priorit
Journal: Eurosurveillance (2010)

Preview this article: Reducing health inequalities and monitoring social determinants of health in the European Union: a priority of the Spanish Presidency of the European Union 2010, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/15/27/art19612-en-1.gif
Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial
Authors: J. Bridgewater, S. Pugh, A. Whitehead, L. Stanton, Z. Eminton, J. Mellor, A. Allen, M. Finch-Jones, S. Falk, T. Iveson, M. Rees, J.W. Valle, J. Hornbuckle, T. Hickish, D. Cunningham, T. Maughan, J. Garden, G. Griffiths, J. Primrose
Journal: Annals of Oncology (2017)
Listeriose na Europa: aumenta a necessidade de uma rede de vigilância europeia
Authors: C Hedberg
Journal: Eurosurveillance (2006)

Ha quatro anos, Henriette de Valk e os seus colegas avaliaram a necessidade e a viabilidade de uma rede europeia dedicada a infeccoes humanas de Listeriosea nos homens. A tal rede era considerada como um meio de reforcar a vigilância em cada pais, harmonizando os metodos microbiologicos e fornecendo instrumentos epidemiologicos para as investigacoes. Os resultados deste enquerito eram claros : os participantes reconheceram que a rede facilitaria a deteccao e a investigacao de surtos e poderia ser baseada nos sistemas nacionais de vigilância existentes. Houve um apoio institucional consideraval para o desenvolvimento de uma rede europeia para Listeria e em resposta aos esforcos de planificacao, a vigilância da listeriosis melhorou em varios paises. No entanto, a rede tem ainda que ser implementada.
Pazopanib and oral cyclophosphamide in women with platinum resistant epithelial ovarian cancers
Authors: S. Gulia, S. Gupta, J. Ghosh, J. Bajpai, A. Maheshwari, R. Kerkar, S. Thumkur, K. Deodhar, M. Thakur
Journal: Annals of Oncology (2017)
Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma
Authors: R. Dummer, P.A. Ascierto, H. Gogas, A. Arance, M. Mandala, G. Liszkay, C. Garbe, D. Schadendorf, I. Krajsová, R. Gutzmer, V. Chiarion Sileni, C. Dutriaux, J.W.B. de Groot, N. Yamazaki, C. Loquai, L.A. de Parseval, M. Pickard, V. Sandor, C. Robert, K.T. Flaherty
Journal: Annals of Oncology (2017)
Timing of initiation of trastuzumab (T) and long-term outcome of patients (pts) with early-stage (ES) HER2-positive (HER2+) breast cancer (BrCa): Impact of neo-adjuvant (NAdj) versus adjuvant (Adj) strategy
Authors: G. Gullo, N. Walsh, D. Fennelly, D. Tryphonopoulos, J. Walshe, K. O'Mahony, N. Silva, L. Hammond, J. Ballot, C. Quinn, C. Buckley, J. Crown
Journal: Annals of Oncology (2017)
Immunological features of resected tumor after neoadjuvant chemotherapy (NAC) and chemoradiotherapy (CRT) become the superior prediction markers for recurrence in rectal cancer
Authors: K. Imaizumi, T. Suzuki, M. Shimomura, Y. Tsukada, T. Sasaki, Y. Nishizawa, M. Kojima, M. Ito, T. Nakatsura
Journal: Annals of Oncology (2017)
Resistance to Cytarabine in Mantle Cell Lymphoma Is Mediated By Down-Regulation of Deoxycytidine Kinase at the Protein Level
Authors: Catja Freiburghaus, Venera Kuci Emruli, Angelica Johansson, Roger Olsson, Fredrik Ek, Christian H Geisler, Mats Jerkeman, Sara Ek
Journal: Blood (2016)
Jumping the Barrier: Modeling Drug Penetration across the Blood–Brain Barrier
Authors: Cody J. Peer, Cindy H. Chau, William D. Figg
Journal: Clinical Cancer Research (2017)

Abstract Determining the penetration of drugs across the blood–brain barrier is a significant challenge in central nervous system drug development. The use of a mechanistic physiologically based pharmacokinetic model can predict drug exposures in the brain without needing in situ drug measurements. Clin Cancer Res; 23(24); 7437–9. ©2017 AACR. See related article by Li et al., p. 7454
Neuropsychiatric adverse events of enzalutamide and abiraterone acetate plus prednisone treatment: Contrasting a meta-analysis of randomized clinical trials with real world reporting patterns from EUDRA
Authors: M. Sanchez Iznaola, R. Parra, G. Angela, J. Casariego, J. MuÑoz Del Toro, P. Robinson
Journal: Annals of Oncology (2017)
Centrifugal Lithography: Centrifugal Lithography: Self‐Shaping of Polymer Microstructures Encapsulating Biopharmaceutics by Centrifuging Polymer Drops (Adv. Healthcare Mater. 19/2017)
Authors: Huisuk Yang, Suyong Kim, Geonwoo Kang, Shayan F. Lahiji, Mingyu Jang, Young Mi Kim, Jae‐Myung Kim, Sang‐Nae Cho, Hyungil Jung
Journal: Advanced Healthcare Materials (2017)

Centrifugal lithography (CL) enables fabrication of microstructures via self-shaping of viscous polymer drops during a centrifugation. Hyungil Jung and co-workers fabricate dissolving microneedles (DMNs) composed of polymer matrix and biopharmaceutics by CL under controlled environments to preserve their activity in article number 1700326. DMNs are penetrated and implanted into skin and delivered their ingredients through the skin to induce biopharmaceutical effects with minimal damage.
Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC)
Authors: J. P. Crown, H. A. Burris, S. Jones, K. M. Koch, A. Fittipaldo, R. Parikh, M. Koehler
Journal: Journal of Clinical Oncology (2007)

1027 Background: Lapatinib (L) is an oral, dual ErbB1/B2 tyrosine kinase inhibitor. T are mainstay of BC treatment. The side-effects seen with T in combination with gefitinib and erlotinib include neutropenia, diarrhea and rash. Based on preclinical synergy, early clinical studies with L and paclitaxel (P) or docetaxel (D) were studied. Methods: We summarize pharmacokinetics (PK) and preliminary safety data from 192 patients. Results: PK analysis for EGF10009 (q3w), show systemic exposure was increased for both L (21%) and P (23%) at doses of 1500mg daily and 175mg/m 2 /q3w, respectively. PK analysis in EGF10021 , (L 1250 mg &amp; D 75 mg/m 2 with prophylactic pegfilgrastim) indicated no significant effect on systemic exposure of either agent. Toxicities across all studies include i.e., for all patients = grade 3, neutropenia (7.3%), diarrhea (18.2%), rash (3.6%). The rate of adverse events for neutropenia and rash were similar to each agent alone, however diarrhea was more common. The frequency and severity of diarrhea was increased in studies EGF10009 and EGF102580 where no proactive treatment of diarrhea was introduced, whereas in EGF105764, with proactive treatment, currently no =grade 3 diarrhea has been reported. The data show that the combination of L and P has clinical activity (&gt;70% RR reported in EGF102580). Conclusions: T plus L combinations have a predictable and manageable safety profile and clinical activity of P plus L combination was observed. Proactive diarrhea management is essential for these combinations. Based on the PK data, no dose adjustments are required, and any dose adjustments should be toxicity-based. Ongoing clinical studies investigating the combinations of L with T, and combinations of L with T plus trastuzumab will be reported in the future. [Table: see text] No significant financial relationships to disclose.
A phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer: the BIONIKK trial
Authors: R.T. Elaidi, S. Oudard, E. Braychenko, C-M. Sun, C. Sautès-Fridman, Y-A. Vano
Journal: Annals of Oncology (2017)
LAG-3 expression in tumor infiltrating immune cells is associated with poor prognosis in patients with microsatellite instability high colon cancer
Authors: I. Lee, S.J. Lee, B.W. Kang, Y.S. Chae, H.J. Kim, S.Y. Park, J.S. Park, G.S. Choi, J.G. Kim
Journal: Annals of Oncology (2017)
Impact of poor prognostic features on the surgical treatment of breast cancer in an intergroup adjuvant chemotherapic trial
Authors: B. A. Pockaj, A. Dueck, K. Tenner, E. Perez
Journal: Journal of Clinical Oncology (2007)

612 Background: The adoption of new breast surgical techniques has been rapid for early stage breast cancer. The utilization of these techniques in patients with high risk operable breast cancer has not been thoroughly investigated. Methods: Retrospective surgical data was summarized for patients entered into N9831 “Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer.” Results: 3,505 patients were entered into N9831 from 2000–2005 following primary surgery for breast cancer. The median age was 50 and 43% were premenopausal. 93% of patients underwent a diagnostic biopsy prior to their definitive surgical procedure. Whether HER2-neu status was available at time of definitive surgery is unknown. 61% underwent a mastectomy whereas 39% underwent breast conserving surgery (BCS). The rate of BCS was relative stable over the course of the trial. Patients with T1 tumors had a higher rate of BCS (49%) compared to T2 tumors (37%) and T3 tumors (6%). Sentinel lymph node (SLN) biopsy was performed in 54% of the cases. The rate of SLN biopsy increased from 40% in 2000 to 66% in 2005. Patients who underwent mastectomy had a lower rate of SLN biopsy than patients who underwent BCS (44% versus 71%, respectively). Tumor size was also associated with the rate of SLN biopsy: T1 (60%), T2 (53%), and T3 (36%). Data on local and regional recurrences are still maturing. Conclusions: Surprisingly, low numbers of patients on this trial underwent BCS whereas the adoption of the SLN biopsy procedure among the same group of surgeons was relatively high. The relatively low rate of BCS in this study population needs further investigation to determine what surgeon and patient factors impacted the surgical decision. No significant financial relationships to disclose.
Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma
Authors: D. Schadendorf, K.T. Flaherty, P. Nathan, P. Hersey, C. Garbe, M. Milhem, L. Demidov, P. Mohr, J.C. Hassel, P. Rutkowski, R. Dummer, J. Utikal, F. Kiecker, J. Larkin, A. D’Amelio, Y. Huang, B. Mookerjee, C. Robert
Journal: Annals of Oncology (2017)
Malaria aeroportuale: nuovi casi nella periferia di Parigi durante l'estate del 1999
Authors: D Lusina, F Legros, V Estève, M Klerlein, T Giacomini
Journal: Eurosurveillance (2000)

Durante l'estate del 1999, in Francia e stato osservato un cluster di quattro casi di malaria aeroportuale. L'analisi dei casi ha rivelato che la malaria aeroportuale, che e una malattia rara, difficile da diagnosticare, puo essere osservata anche in persone che non fanno professioni a rischio, per esempio nei residenti vicino agli aeroporti. Quest'analisi sottolinea anche l'importanza di aderire alle raccomandazioni per il trattamento contro gli insetti degli aerei provenienti da aree malariche e l'importanza di aspetti ematologici indiretti, in particolare della trombocitopenia.
Safety vs Efficacy of Lowering Blood Pressure—Reply
Authors: Clyde W. Yancy, Robert O. Bonow
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Quality-of-life results from a randomized, phase-II-study of the therapeutic cancer vaccine L-BLP25 (Stimuvax®) in the preoperative treatment of women with primary breast cancer (ABCSG-34)
Authors: V. Bjelic-Radisic, C.F. Singer, G. Pfeiler, M. Hubalek, R. Bartsch, H. Stöger, A. Pichler, E. Petru, R. Greil, V. Wette, A. Petzer, P. Sevelda, D. Egle, P. Dubsky, F. Fitzal, R. Jakesz, M. Balic, S. Frantal, L. Sölkner, M. Gnant
Journal: Annals of Oncology (2017)
Isoform-specific functions in pancreatic adenocarcinoma
Authors: H. Arasanz, M. Zuazo-Ibarra, M. Gato-Cañas, M. Ibáñez-Vea, G. Fernández-Hinojal, J. Fernández-Irigoyen, E. Santamaria, G. Kochan, R. Vera, D. Escors
Journal: Annals of Oncology (2017)
Un système national de surveillance syndromique en Angleterre et au Pays de Galles basé sur une ligne d’alerte téléphonique
Authors: G E Smith, D L Cooper, P Loveridge, F Chinemana, E Gerard, N Verlander
Journal: Eurosurveillance (2006)

Les donnees de soins primaires recueillies en routine fournissent un moyen de surveiller un grand nombre de syndromes pouvant etre des signes pour des alertes precoces de menaces de la sante publique. Au Royaume-Uni, un systeme national de surveillance syndromique, gere conjointement par l’Institut de sante publique anglais (Health Protection Agency, HPA) et NHS Direct (un numero national d’aide aux patients), analyse les symptomes rapportes a NHS Direct. L’objectif de ce systeme est d’identifier une augmentation des syndromes caracteristiques d’infections et maladies courantes, ou les stades precoces de maladies dues a la dissemination volontaire d’agents biologiques ou chimiques. Les donnees relatives a 11 symptomes/syndromes cle sont envoyees par courrier electronique par les 22 centres d’appel de NHS Direct couvrant l’Angleterre et le Pays de Galles et analysees quotidiennement par le HPA. Les exces d’appels statistiquement significatifs sont identifies automatiquement et evalues par une equipe multidisciplinaire. Le systeme de surveillance a souligne plusieurs augmentations soudaines des syndromes rapportes a NHS Direct, mais aucune evidence d’une attaque biologique ou chimique n’a ete detectee. Ce systeme constitue cependant un outil d’alerte precoce et de suivi des augmentations de morbidite dans la communaute (par exemple, les syndromes grippaux, les coups de chaleur) ; il permet egalement de rassurer la population lors de periodes de perception de risques eleves (comme apres les bombes du 7 juillet 2005 a Londres, ou l’incendie du depot de carburant de Buncefield en decembre 2005) ; enfin ce systeme fournit des donnees de surveillance rapides pour les plans de preparation de pandemie grippale et la modelisation epidemique.
GW28-e0750 New Test Confirms Accurately Heart Failure or Not in Patients after TAVR or MitraClip
Authors: Thach Nguyen, Bui Pham Thai Hoa, Hanh Nguyen Hieu Le, Tuan Si Nguyen, Luong Thanh Phuoc, Gianluca Rigatelli
Journal: Journal of the American College of Cardiology (2017)
Relevance between PD-L1 and radiological invasiveness in pathological stage I lung adenocarcinoma
Authors: G. Toyokawa, K. Takada, T. Okamoto, Y. Kozuma, T. Matsubara, S. Takamori, T. Akamine, M. Katsura, F. Shoji, Y. Maehara
Journal: Annals of Oncology (2017)
Impact of hyperbaric oxygenation on the expression of PKD1 protein forms in T98G glioblastoma cell line treated with selected pentabromobenzylisothiourea (ZKK-3)
Authors: K. Stepien, R.P. Ostrowski, E.B. Pucko, E. Grzywaczewska, E. Matyja
Journal: Annals of Oncology (2017)
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Authors: Masatoshi Kudo, Ann-Lii Cheng, Joong-Won Park, Jae Hyung Park, Po-Chin Liang, Hisashi Hidaka, Namiki Izumi, Jeong Heo, Youn Jae Lee, I-Shyan Sheen, Chang-Fang Chiu, Hitoshi Arioka, Satoshi Morita, Yasuaki Arai
Journal: The Lancet. Gastroenterology & hepatology (2017)
Evalution of effect of Vitamin D levels and tumor Vitamin D receptor status as a risk factor and marker for therapeutic response Indian breast cancer patients.
Authors: Kul Ranjan Singh, Abhinav Arun Sonkar, Prarthana Saxena, Jitendra Kumar Kushwaha, Akshay Anand Agarwal, Nuzhat Husain
Journal: Journal of Clinical Oncology (2015)

e12523 Background: Vitamin D has been proposed to have pathophysiological role in Breast cancer. Vitamin D receptor (VDR) has also been is a mediator for cellular effects of Vitamin D and interacts with various cell signalling pathways that influence breast cancer development and progression. These associations have not been consistenlty proved. The present study aims to study the role of serum Vitamin D levels as a risk factor for cancer breast and VDR as a prognostic marker for response to chemotherapy. Methods: 82 patients diagnosed with carcinoma breast and receiving standard treatment in Department of Surgery, King George’s Medical University between January 2012 and December 2012 were included . Vitamin D receptor expression was determined in the tumor tissue sample and graded with Immuno Reactivity Scores(IRS). 65 patients admitted for non cancer elective surgery served as controls for serum Vitamin D levels and 36 patients served as controls for VDR status. The study patients were followed up and tumor response studied as per WHO response criteria in those receiving Neo adjuvant chemotherapy. Results: A higher prevalence of deficient serum vitamin D levels in carcinoma breast patients (67.07%) was noted as compared to prevalence of deficiency in patients admitted for non-cancer elective surgery (31.25%). A significant down-regulation of VDR in carcinoma breast tissue (mean immunoreactivity (IRS) score = 2.24+/-3.18) was present as compared to benign breast lesions (mean IRS score of = 6.41+/-1.54)`(p = 0.001). The probability of complete response after neo-adjuvant chemotherapy was significantly greater in VDR positive cases and further greater in those high IRS group. 76.92% of patients with complete response to chemotherapy were VDR positive. Conclusions: Vitamin D defeciency is common in Breast cancer patients and may be a risk factor for Development of cancer Breast. immuno-histochemical assessment of Vitamin D receptor (VDR) may be used as a predictor of therapeutic response of carcinoma breast.
Biosensing: Graphene Field‐Effect Transistors for the Sensitive and Selective Detection of <i>Escherichia coli</i> Using Pyrene‐Tagged DNA Aptamer (Adv. Healthcare Mater. 19/2017)
Authors: Guangfu Wu, Ziwen Dai, Xin Tang, Zihong Lin, Pik Kwan Lo, M. Meyyappan, King Wai Chiu Lai
Journal: Advanced Healthcare Materials (2017)

An aptamer modified graphene field-effect transistor (G-FET) based biosensor for electrical detection of E. coli is developed by King Wai Chiu Lai and co-workers in article number 1700736. The change of the carrier density in graphene due to the attachment of E. coli is correlated with the electrical response of the graphene biosensors. The electrical response is analyzed and optimized by tuning the gate voltage which affects the carrier mobility of graphene. The excellent sensing performance (high sensitivity, selectivity and stability) opens up the possibility to utilize aptamer modified graphene device for pathogens detection in food and water quality monitoring and early diagnosis of pathogen infections.
Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.
Authors: Michael Friedlander, Val Gebski, Emma Gibbs, Ralph Bloomfield, Felix Hilpert, Lari B. Wenzel, Florence Joly, Daniel Eek, Manuel Rodrigues, Andrew R. Clamp, Richard T. Penson, Diane M. Provencher, Jacob Korach, Tomasz Huzarski, Laura Vidal, Vanda Salutari, Clare L. Scott, Maria Ornella Nicoletto, Kenji Tamura, Eric Pujade-Lauraine
Journal: Journal of Clinical Oncology (2017)

5507 Background: The median PFS after chemotherapy in PSR SOC is less than 6 months in many patients. In SOLO2 (ENGOT Ov-21; NCT01874353), maintenance olaparib (O) given after response to chemotherapy resulted in a significant improvement in PFS vs placebo (P) in patients with g BRCAm PSR SOC (hazard ratio [HR] 0.30, 95% CI 0.22, 0.41; P&lt;0.0001; median 19.1 vs 5.5 months; 63% data maturity; Pujade-Lauraine et al. SGO 2017). Our a priori hypothesis was that maintenance therapy with O would not negatively impact HRQOL compared with P and would be associated with additional patient-centered benefits to support the prolongation of PFS, the primary endpoint of SOLO2. Methods: HRQOL was evaluated by the Functional Assessment of Cancer Therapy-Ovarian Trial Outcome Index (FACT-O TOI) in all 295 patients. This measures functional and physical well-being and symptoms, including adverse events. Change from baseline in FACT-O TOI score during the first 12 months was the primary HRQOL analysis (mixed model repeated measures). Secondary planned analyses included duration of ‘good quality of life’ by time without symptoms of disease or toxicity (TWiST) and quality-adjusted PFS (QAPFS; a single measure of PFS and HRQOL outcomes). Results: There was no significant detrimental effect of O vs P on HRQOL analyzed by change from baseline in TOI score (–3.1 vs –2.9, respectively, difference (O minus P) –0.2; 95% CI –2.4, 2.1; P=0.88). There was a significant improvement for patients on maintenance O in TWiST (13.5 vs 7.2 months, difference 6.3; 95% CI 2.9, 8.6; P&lt;0.001) and QAPFS (mean 14.0 vs 7.3 months for O and P, respectively, difference 6.7; 95% CI 5.0, 8.5; P&lt;0.0001). Conclusions: Maintenance O did not detrimentally impact HRQOL relative to P. The significant improvement in PFS with O was associated with additional patient-centered benefits, including a longer duration without symptoms of disease or treatment toxicity and longer QAPFS. Clinical trial information: NCT01874353.